Sponsored Links
| CEL-SCI Corporation Receives Government Approval From Taiwan To Commence Phase III Clinical Trial Of Multikine In Head And Neck Cancer |
 |
 |
 |
| Medical News - Ear, Nose and Throat | |||
|
CEL-SCI Corporation (NYSE AMEX: CVM) announced it has received governmental approval from the Taiwanese Department of Health to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Taiwan. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer... Read more: Ear, Nose and Throat News From Medical News Today
|